DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,008 filers reported holding DANAHER CORPORATION in Q1 2022. The put-call ratio across all filers is 1.38 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $179,103,244 | +19.8% | 721,899 | +15.9% | 0.13% | +36.7% |
Q2 2023 | $149,480,454 | -1.6% | 622,835 | +3.3% | 0.10% | -7.5% |
Q1 2023 | $151,935,010 | -1.5% | 602,821 | +3.7% | 0.11% | -13.8% |
Q4 2022 | $154,309,969 | +2.9% | 581,380 | +0.2% | 0.12% | +15.0% |
Q3 2022 | $149,913,000 | -1.9% | 580,407 | -3.7% | 0.11% | -6.1% |
Q2 2022 | $152,851,000 | -22.5% | 602,923 | -10.4% | 0.11% | -5.0% |
Q1 2022 | $197,327,000 | -25.4% | 672,717 | -16.4% | 0.12% | -15.5% |
Q4 2021 | $264,608,000 | +13.7% | 804,253 | +5.2% | 0.14% | +3.6% |
Q3 2021 | $232,805,000 | +8.6% | 764,694 | -4.3% | 0.14% | +6.2% |
Q2 2021 | $214,404,000 | +6.5% | 798,941 | -10.7% | 0.13% | -1.5% |
Q1 2021 | $201,346,000 | +9.5% | 894,553 | +8.0% | 0.13% | +20.2% |
Q4 2020 | $183,955,000 | +19.5% | 828,100 | +15.8% | 0.11% | +7.9% |
Q3 2020 | $153,998,000 | +41.7% | 715,175 | +16.4% | 0.10% | +20.2% |
Q2 2020 | $108,666,000 | -26.8% | 614,525 | -42.7% | 0.08% | -37.3% |
Q1 2020 | $148,387,000 | -1.9% | 1,072,087 | +8.8% | 0.13% | +21.8% |
Q4 2019 | $151,299,000 | +28.9% | 985,781 | +21.3% | 0.11% | +18.3% |
Q3 2019 | $117,354,000 | -20.7% | 812,532 | -21.5% | 0.09% | -22.5% |
Q2 2019 | $147,913,000 | +83.1% | 1,034,933 | +69.1% | 0.12% | +55.8% |
Q1 2019 | $80,788,000 | +23.6% | 611,942 | -3.4% | 0.08% | +14.9% |
Q4 2018 | $65,343,000 | -27.8% | 633,667 | -23.9% | 0.07% | -17.3% |
Q3 2018 | $90,481,000 | +124.1% | 832,683 | +103.5% | 0.08% | +125.0% |
Q2 2018 | $40,379,000 | -56.4% | 409,187 | -56.7% | 0.04% | -52.6% |
Q1 2018 | $92,587,000 | +4.1% | 945,630 | -1.3% | 0.08% | +5.6% |
Q4 2017 | $88,964,000 | +14.5% | 958,444 | +5.8% | 0.07% | +12.5% |
Q3 2017 | $77,728,000 | +38.2% | 906,144 | +36.0% | 0.06% | +25.5% |
Q2 2017 | $56,235,000 | +3.4% | 666,358 | +4.8% | 0.05% | +6.2% |
Q1 2017 | $54,362,000 | -62.6% | 635,570 | -66.0% | 0.05% | -63.4% |
Q4 2016 | $145,325,000 | +216.5% | 1,866,957 | +218.7% | 0.13% | +204.7% |
Q3 2016 | $45,919,000 | -38.7% | 585,777 | -21.1% | 0.04% | -44.2% |
Q2 2016 | $74,957,000 | +76.0% | 742,140 | +65.3% | 0.08% | +60.4% |
Q1 2016 | $42,588,000 | -40.4% | 448,952 | -41.6% | 0.05% | -32.4% |
Q4 2015 | $71,434,000 | +30.9% | 769,088 | +20.1% | 0.07% | +42.0% |
Q3 2015 | $54,563,000 | -77.6% | 640,341 | -77.4% | 0.05% | -76.9% |
Q2 2015 | $243,292,000 | +144.2% | 2,836,902 | +141.8% | 0.22% | +125.0% |
Q1 2015 | $99,616,000 | +51.2% | 1,173,318 | +52.6% | 0.10% | +62.7% |
Q4 2014 | $65,900,000 | +2.2% | 768,851 | -9.4% | 0.06% | +3.5% |
Q3 2014 | $64,469,000 | -18.7% | 848,483 | -15.7% | 0.06% | -26.0% |
Q2 2014 | $79,279,000 | +104.7% | 1,006,961 | +95.0% | 0.08% | +92.5% |
Q1 2014 | $38,734,000 | -45.2% | 516,456 | -43.6% | 0.04% | -37.5% |
Q4 2013 | $70,683,000 | +1.0% | 915,576 | -9.3% | 0.06% | -1.5% |
Q3 2013 | $69,981,000 | +47.7% | 1,009,527 | +34.9% | 0.06% | +38.3% |
Q2 2013 | $47,387,000 | – | 748,608 | – | 0.05% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
Third Point | 2,450,000 | $607,845,000 | 9.22% |
Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |